-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Matinas BioPharma Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2023.
- Matinas BioPharma Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$5.72M, a 5.63% increase year-over-year.
- Matinas BioPharma Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$22.9M, a 10.9% decline year-over-year.
- Matinas BioPharma Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.9M, a 9.26% decline from 2022.
- Matinas BioPharma Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$21M, a 9.82% increase from 2021.
- Matinas BioPharma Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$23.3M, a 3.73% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)